ENANTA PHARMACEUTICALS, INC Cash and Cash Equivalents, Period Increase (Decrease)
ENANTA PHARMACEUTICALS, INC (ENTA) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$1.77 million for the 12-month period ending 2018-09-30, per its 10-K filed 2018-11-29.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-11-29
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $21.43M, a 50.65% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$24.45M, a 901.08% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$1.13M.
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $2.38M, a 41.15% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$1.77M, a 103.61% decline from fiscal 2017.
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was $49.10M.
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$5.15M.
- ENANTA PHARMACEUTICALS, INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$8.97M, a 141.09% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-09-30 | $21.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | -$3.02M derived: sum of 2 quarters · filed 2018-11-29 | -$4.15M derived: sum of 3 quarters · filed 2018-11-29 | -$1.77M 10-K · filed 2018-11-29 |
| 2018-06-30 | -$24.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-09 | -$25.58M derived: sum of 2 quarters · filed 2018-08-09 | -$23.20M 10-Q · filed 2018-08-09 | $20.21M derived: sum of 4 quarters · filed 2018-11-29 |
| 2018-03-31 | -$1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10 | $1.25M 10-Q · filed 2018-05-10 | $44.66M derived: sum of 3 quarters · filed 2018-11-29 | $47.72M derived: sum of 4 quarters · filed 2018-11-29 |
| 2017-12-31 | $2.38M 10-Q · filed 2018-02-09 | $45.79M derived: sum of 2 quarters · filed 2018-11-29 | $48.84M derived: sum of 3 quarters · filed 2018-11-29 | $47.44M derived: sum of 4 quarters · filed 2018-11-29 |
| 2017-09-30 | $43.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | $46.46M derived: sum of 2 quarters · filed 2018-11-29 | $45.06M derived: sum of 3 quarters · filed 2018-11-29 | $49.10M 10-K · filed 2018-11-29 |
| 2017-06-30 | $3.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-09 | $1.65M derived: sum of 2 quarters · filed 2018-08-09 | $5.69M 10-Q · filed 2018-08-09 | -$2.53M derived: sum of 4 quarters · filed 2018-11-29 |
| 2017-03-31 | -$1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10 | $2.63M 10-Q · filed 2018-05-10 | -$5.58M derived: sum of 3 quarters · filed 2018-11-29 | -$37.15M derived: sum of 4 quarters · filed 2018-11-29 |
| 2016-12-31 | $4.04M 10-Q · filed 2018-02-09 | -$4.17M derived: sum of 2 quarters · filed 2018-11-29 | -$35.74M derived: sum of 3 quarters · filed 2018-11-29 | -$25.61M derived: sum of 4 quarters · filed 2018-11-29 |
| 2016-09-30 | -$8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | -$39.78M derived: sum of 2 quarters · filed 2018-11-29 | -$29.66M derived: sum of 3 quarters · filed 2018-11-29 | -$5.15M 10-K · filed 2018-11-29 |
| 2016-06-30 | -$31.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09 | -$21.44M derived: sum of 2 quarters · filed 2017-08-09 | $3.06M 10-Q · filed 2017-08-09 | $4.95M derived: sum of 4 quarters · filed 2017-12-11 |
| 2016-03-31 | $10.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10 | $34.63M 10-Q · filed 2017-05-10 | $36.52M derived: sum of 3 quarters · filed 2017-12-11 | $30.61M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-12-31 | $24.51M 10-Q · filed 2017-02-09 | $26.39M derived: sum of 2 quarters · filed 2017-12-11 | $20.48M derived: sum of 3 quarters · filed 2017-12-11 | $12.10M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-09-30 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | -$4.03M derived: sum of 2 quarters · filed 2017-12-11 | -$12.40M derived: sum of 3 quarters · filed 2017-12-11 | -$8.97M 10-K · filed 2017-12-11 |
| 2015-06-30 | -$5.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | -$14.29M derived: sum of 2 quarters · filed 2016-08-09 | -$10.86M 10-Q · filed 2016-08-09 | -$6.53M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-03-31 | -$8.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | -$4.95M 10-Q · filed 2016-05-10 | -$623.00K derived: sum of 3 quarters · filed 2016-12-09 | $7.65M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-12-31 | $3.43M 10-Q · filed 2016-02-09 | $7.76M derived: sum of 2 quarters · filed 2016-12-09 | $16.03M derived: sum of 3 quarters · filed 2016-12-09 | $29.70M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-09-30 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $12.60M derived: sum of 2 quarters · filed 2016-12-09 | $26.27M derived: sum of 3 quarters · filed 2016-12-09 | $21.84M 10-K · filed 2016-12-09 |
| 2014-06-30 | $8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10 | $21.95M derived: sum of 2 quarters · filed 2015-08-10 | $17.52M 10-Q · filed 2015-08-10 | $7.50M derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-03-31 | $13.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08 | $9.24M 10-Q · filed 2015-05-08 | -$777.00K derived: sum of 3 quarters · filed 2015-12-11 | -$56.36M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-12-31 | -$4.43M 10-Q · filed 2015-02-06 | -$14.45M derived: sum of 2 quarters · filed 2015-12-11 | -$70.04M derived: sum of 3 quarters · filed 2015-12-11 | -$16.31M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-09-30 | -$10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | -$65.61M derived: sum of 2 quarters · filed 2015-12-11 | -$11.88M derived: sum of 3 quarters · filed 2015-12-11 | -$1.65M 10-K · filed 2015-12-11 |
| 2013-06-30 | -$55.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12 | -$1.86M derived: sum of 2 quarters · filed 2014-08-12 | $8.37M 10-Q · filed 2014-08-12 | $14.92M derived: sum of 4 quarters · filed 2014-12-11 |
| 2013-03-31 | $53.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12 | $63.95M 10-Q · filed 2014-05-12 | $70.50M derived: sum of 3 quarters · filed 2014-12-11 | $53.76M derived: sum of 4 quarters · filed 2014-12-11 |
| 2012-12-31 | $10.22M 10-Q · filed 2014-02-13 | $16.77M derived: sum of 2 quarters · filed 2014-12-11 | $33.00K derived: sum of 3 quarters · filed 2014-12-11 | |
| 2012-09-30 | $6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11 | -$10.19M derived: sum of 2 quarters · filed 2014-12-11 | $3.67M 10-K · filed 2014-12-11 | |
| 2012-06-30 | -$16.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12 | -$2.88M 10-Q · filed 2013-08-12 | ||
| 2012-03-31 | $13.87M 10-Q · filed 2013-05-15 | |||
| 2011-09-30 | $6.37M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |